Treatment guidelines – Treatment access

Oliviu Pascu
Treatment of chronic hepatitis C in Romania

- 2003-2015: Interferon based treatment
- 2016: Treatment of compensated cirrhosis with DAA
- 2017: Treatment of chronic hepatitis (F3), compensated cirrhosis (F4) and decompensated cirrhosis with DAA.
I. Interferon based therapy

- 2000- 5000 patients /year
- Hepatitis F2-F3-F4
- Selected centers – Central Committee for approval
I. Interferon based therapy

<table>
<thead>
<tr>
<th>No of patients</th>
<th>Severity assessment</th>
<th>SVR</th>
<th>nonresponders</th>
</tr>
</thead>
<tbody>
<tr>
<td>56 000</td>
<td>Liver biopsy</td>
<td>48-50%</td>
<td>~30 000</td>
</tr>
</tbody>
</table>
II. 2016-Compensated Cirrhosis
Ombitasvir+Paritaprevir+ Ritonavir + Dasabuvir

<table>
<thead>
<tr>
<th>No patients</th>
<th>Severity assessment</th>
<th>SVR</th>
<th>prescribing physicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>6000</td>
<td>LB- Fibromax</td>
<td>&gt; 99%</td>
<td>11 centers (G-ID)</td>
</tr>
</tbody>
</table>
### III. 2017-Chronic Hepatitis (f3)-compensated cirrhosis (f4) (Ombitasvir+Paritaprevir+ Ritonavir + Dasabuvir)

<table>
<thead>
<tr>
<th>No of approved patients</th>
<th>No of treated patients</th>
<th>SVR</th>
<th>prescribing physicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 000</td>
<td>7000</td>
<td>99%</td>
<td>11 centers (G+ID)</td>
</tr>
</tbody>
</table>
### III.2017- Decompensated cirrhosis (Sofosbuvir+Ledipasvir)

<table>
<thead>
<tr>
<th>No of approved patients</th>
<th>No of treated patients</th>
<th>SVR</th>
<th>prescribing physicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>700</td>
<td>90-95%</td>
<td>11 centers (G)</td>
</tr>
</tbody>
</table>
The future: 2018-2019

- We asked MH to change the low-cost-volume because we only had one molecule available. The low was changed- and probably we will have 2 or 3 molecules(combination)
- We intend to include patients with F1 and F2 without discrimination.
- We intend to recommend the extensive use of non-invasive and inexpensive assessment methods: Fibroscan, APRI
- We want to extend the area of prescriptions to all county hospitals
- We intend to make a simple and easy to apply Protocol
Where 110 million disappeared in 2 years?

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 180 million.
It's the same situation in Romania?

- We had 30,000 non-responders in 2015
- We found only 13,000 patients (2016-2017) to be included in treatment
- 17,000 have disappeared
- If the proportion remains, we may have only 150,000 to 200,000 infected patients not 500,000-600,000
- This requires adaptation of the screening and treatment strategy.
Thank you very much